VILINBIO Stock Overview
Vilin Bio Med Limited engages in the manufacture and sale of pharmaceutical products in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vilin Bio Med Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹21.00 |
| 52 Week High | ₹30.45 |
| 52 Week Low | ₹18.10 |
| Beta | 0 |
| 1 Month Change | 10.53% |
| 3 Month Change | -15.32% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| VILINBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.0% | 2.3% | 2.6% |
| 1Y | n/a | 56.7% | 45.0% |
Return vs Industry: Insufficient data to determine how VILINBIO performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VILINBIO performed against the Indian Market.
Price Volatility
| VILINBIO volatility | |
|---|---|
| VILINBIO Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: VILINBIO's share price has been volatile over the past 3 months.
Volatility Over Time: VILINBIO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Viswa Sadhanala | www.vilinbiomed.co.in |
Vilin Bio Med Limited engages in the manufacture and sale of pharmaceutical products in India. The company provides cardiovascular, musculo-skeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system and anti-allergic, anti- diabetic, and miscellaneous drugs, as well as multi-vitamins, minerals, and amino acids supplements. It offers products in the form of solid oral dosages, such as tablets and capsules; oral liquids comprising syrups, suspensions, and dry powders; and external preparations.
Vilin Bio Med Limited Fundamentals Summary
| VILINBIO fundamental statistics | |
|---|---|
| Market cap | ₹292.95m |
| Earnings (TTM) | ₹14.63m |
| Revenue (TTM) | ₹159.93m |
20.0x
P/E Ratio1.8x
P/S RatioIs VILINBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VILINBIO income statement (TTM) | |
|---|---|
| Revenue | ₹159.93m |
| Cost of Revenue | ₹96.81m |
| Gross Profit | ₹63.12m |
| Other Expenses | ₹48.49m |
| Earnings | ₹14.63m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.05 |
| Gross Margin | 39.47% |
| Net Profit Margin | 9.15% |
| Debt/Equity Ratio | 23.6% |
How did VILINBIO perform over the long term?
See historical performance and comparison